Abstract
To explore the effects of various antihypertensive regimes on microalbuminuria, an angiotensin II receptor blocker (ARB), valsartan, was substituted for or added to treatment with a calcium channel blocker (CCB). After a 6-month CCB baseline period, 28 Japanese hypertensive patients with incipient diabetic nephropathy (defined as a urinary albumin excretion [UAE] of 30–300 mg/g creatinine), were assigned to two groups according to their blood pressure (BP) levels: in patients with a BP of more than 130/85 mmHg (n=17), valsartan was added to the CCB (Group A), while in patients with a BP <130/85 mmHg, valsartan alone was given (Group B: n=11) for 12 months. UAE was determined before and at 3, 6 and 12 months after the initiation of ARB. Although the initial BP was significantly higher in Group A (150/83 mmHg) than Group B (127/77 mmHg), BP was decreased to 141/78 mmHg in Group A and slightly, but not significantly, increased to 130/82 mmHg in Group B. In both groups, UAE was significantly decreased after ARB treatment (to 89% of the basal value in Group A and to 40.5% of the basal value in Group B) and did not differ each other and the amount of decrease did not differ significantly between the two groups. These results suggest that combination therapy with an ARB and CCB is very effective in lowering BP and UAE in cases in which BP is not well controlled, while, even in patients with a sufficient BP control of <130/85 mmHg, the use of ARB singly resulted in a significant decrease in UAE without a further decrease in BP, implying that the ARB had a renoprotective action independent of changes in BP.
Similar content being viewed by others
Article PDF
References
Statistic Committee of Japan Hemodialysis Society : An overview of dialysis treatment in Japan (as of Dec. 31, 2003). J Jpn Hemodialysis Soc 2006; 39: 1–22 ( in Japanese).
Mogensen CE : Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383–388.
Kaiske BL, Kalil RSN, Ma JZ, et al: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–138.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborate Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
Parving H, Lehnert H, Broncher-Mortensen J, et al: The effect of irbesartan on the progression of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators : Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure–independent effect. Circulation 2002; 106: 672–678.
Zatz R, Dunn R, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925–1930.
Imai E, Horio M : Prevalence and perspectives of CKD in Japan. Jpn J Nephrol 2006; 48: 703–710 ( in Japanese).
Doublier S, Salvidio G, Lupia E, et al: Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023–1030.
Duruvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical stress. Kidney Int 2004; 65: 30–39.
Baba S, The J-MIND Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191–201.
Nathan S, Pepine CJ, Bakris GL : Calcium antagonists. Effects on cardio-renal risk in hypertensive patients. Hypertension 2005; 46: 637–642.
Katayama S, Inaba M, Morita T, et al: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601–605.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Ritz E, Orth SR, Strzelczyk P : Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 ( Suppl 2): S21–S26.
Bakris GL, Griffin KA, Picken MM, Bidani AK : Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997; 15: 1181–1185.
Okuda N, Hayashi T, Mori T, et al: Nifedipine enhances the cardioprotective effect of an angiotensin II–receptor blocker in an experimental animal model of heart failure. Hypertens Res 2005; 28: 431–438.
Jinno T, Iwai M, Li Z, et al: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263–269.
Mak TI, Boehme P, Wegliccki WB : Antioxidant effect of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992; 70: 1099–1103.
Ko YD, Sachinidis A, Graack GH, et al: Inhibition of angiotensin II and platelet-derived growth factor–induced vascular smooth muscle cell proliferation by calcium entry blockers. Clin Invest 1992; 70: 113–117.
Klag MJ, Whelton PK, Randal BL, et al: A prospective study of blood pressure and incidence of end-stage renal disease in 332,544 men. N Engl J Med 1996; 334: 13–18.
Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, The Modification of Diet in Renal Disease Study Group: Achievment and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29: 641–650.
UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. BMJ 1998; 317: 703–713.
Lewis JB, Berl T, Bain RP, et al: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809–817.
Araki S, Haneda M, Sugimoto T, et al: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54: 2983–2987.
Yamada T, Komatsu M, Komiya I, et al: Development, progression, and regression of microalbuminuria in Jpanese patients with type 2 diabetes under tight glycemic and blood pressure control. Diabetes Care 2005; 28: 2733–2738.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katayama, S., Yagi, S., Yamamoto, H. et al. Is Renoprotection by Angiotensin Receptor Blocker Dependent on Blood Pressure?: The Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) Study. Hypertens Res 30, 529–533 (2007). https://doi.org/10.1291/hypres.30.529
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.529
Keywords
This article is cited by
-
Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression
Molecular Biology Reports (2021)